Back to News
Market Impact: 0.15
Sword Bio and Alturas Analytics Announce Strategic Bioanalytical Collaboration
Source: PRWeb
Healthcare & Biotech
Sword Bio and Alturas Analytics announced a strategic collaboration to give biotechnology and pharmaceutical companies coordinated access to complementary bioanalytical capabilities for large- and small-molecule drug development. The announcement provided no financial terms or additional quantitative details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma
- Bottoms Says Georgia Needs Pause on New Data Centers
- Genmab shares jump 13% on colorectal cancer drug trial results